学院介绍

意大利赞邦制药联合丁香园搭建“呼吸施tyle-网络精英学院”,该学院由呼吸领域权威专家为您讲解最新的治疗理念,分享最新的资讯文献,供广大呼吸科医生分享、学习;每期专家课堂学习完成后,还可参加当堂小测试,便于大家巩固学习内容、掌握重要知识点... 查看更多

查看更多

文献资讯

1PANTHEON Study 2014 LANCET RESPIRATORY-英文版

COPD is characterised by persistent airflow limitation and frequent recurrent acute exacerbations that contribute to disease severity in individual patients.COPD with acute exacerbations results in a faster decline in lung function,impairment of health tatus, reduction in exercise tolerance, and high economic burden,leading to substantial rates of hospital admission, readmission and mortality. Therefore, effective prevention and treatment of exacerbations has been strongly recommended by the Global Initiative for Chronic Obstructive Lung Disease (GOLD).

2Oxidative stress and air pollution exposure

Air pollution is associated with increased cardiovascular and pulmonary morbidity and mortality. The mechanisms of air pollution-induced health effects involve oxidative stress and inflammation. As a matter of fact, particulate matter (PM), ozone, nitrogen oxides, and transition metals, are potent oxidants or able to generate reactive oxygen species (ROS). Oxidative stress can trigger redox-sensitive pathways that lead to different biological processes such as inflammation and cell death. However, it does appear that the susceptibility of target organ to oxidative injury also depends upon its ability to upregulate protective scavenging systems.

1 口服N-乙酰半胱氨酸可减轻鼠体内博莱霉素所致肺损伤并降低黏蛋白Muc5ac表达

Oxidative stress is involved in the pathogenesis of pulmonary fibrosis, therefore antioxidants may be of therapeutic value. Clinical work indicates that Nacetylcysteine (NAC) may be beneficial in this disease. The activity of this antioxidant was examined on bleomycin-induced lung damage, mucus secretory cells hyperplasia and mucin Muc5ac gene expression in rats.

2PANTHEON Study 2014 LANCET RESPIRATORY-中文版

氧化应激增高和炎症在慢性阻塞性肺疾病(COPD)的发病机理中具有一定作用。具有抗氧化和抗炎作用的药物,如N-乙酰半胱氨酸可能是治疗COPD的有效方法。本文的目标是评估N-乙酰半胱氨酸能否降低COPD患者的急性加重率。

1儿童常见呼吸道疾病雾化吸入治疗专家共识

目前的静脉注射用药,无论是在药物选择,还是配伍方面都有一定的安全用药参考信息,可供临床医师、药剂师和护士参考。然而,关于雾化吸入治疗的用药方案以及药物配伍的信息却非常有限。近期美国发表的常用雾化吸入药物混合配伍指南采用了易于使用的表格形式,为临床提供了可供雾化吸入的药物及其配伍的各种参考信息。我们在该指南基础上,结合中国呼吸道疾病雾化吸入治疗现状,制定了儿童雾化吸入治疗共识,根据不同疾病提出了雾化治疗推荐方案,供临床医师参考。

2Advances in inhalation therapy in pediatrics

To review the most relevant articles regarding the technical aspects of inhalation therapy, inhalers currently available, and especially major advances in inhalation therapy in pediatrics. Sources:Articles of MEDLINE database from 1983 were reviewed, in addition to book chapters, and the most important studies were selected according to the criteria established for this article. For children younger than 8 years, pressurized metered-dose inhalers with spacers are the most appropriate devices, since they provide a practical approach associated with greater lung deposition. In children older than 8 years who can generate high inspiratory flow rates, dry powder devices are best suited.

1An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias

In 2002 the American Thoracic Society/European Respiratory Society (ATS/ERS) classification of idiopathic interstitial pneumonias (IIPs) defined seven specific entities, and provided standardized terminology anddiagnosticcriteria.In addition,the historical “gold standard” of histologic diagnosis was replaced by a multidisciplinary approach. Since 2002 many publications have provided new information about IIPs. The objective of this statement is to update the 2002 ATS/ERS classification of IIPs.

22011年特发性肺纤维化诊断和治疗循证新指南解读

2000年美国胸科学会/欧洲呼吸学会( ATS/ERS) 发表了特发性肺纤维化( idiopathicpulmonaryfibrosis,IPF) 诊断和治疗的共识历经11年,IPF的临床和基础研究均取得了许多重要进展 2011年来自美国胸科学会( AmericanThoracicSociety,ATS) 欧洲呼吸学会(EuropeanRespiratorySociety,ERS) 日本呼吸学会( Japanese Respiratory Society,JRS) 和拉丁美洲胸科学会( Latin American ThoracicAssociation,ALAT) 的间质性肺疾病( ILD) 特发性间质性肺炎( IIP) 和IPF领域的著名专家,系统回顾了2010年5月前有关IPF的文献,共同制定了第一部以循证为基础的IPF诊断和治疗指南( 简称2011指南) , 于2011年3月正式颁布2011指南涵盖当今对IPF的最新知识,囊括IPF定义流行病学危险因素诊断自然病史分期与预后治疗和疾病过程监控将来的研究方向等多方面的内容 限于篇幅,本文对2011指南中的主要内容作一简介,以飨国内同道。

网友评论

评论内容包含敏感词,已自动屏蔽
daxiuge 发表于 白春学教授 2018-12-24 14:47
很友好的教授
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀
dxy_s5qhgrr3 发表于 白春学教授 2018-12-21 23:32
优秀

VIP邀请

如果你有专区VIP邀请码,输入后优先获得100积分

学院排名

NO.1 ccc2 积分:3485
NO.2 lh505 积分:2725
NO.3 zxb597 积分:2485
NO.4 liying2011 积分:2440
NO.5 chiredebingyu 积分:2360
更多 >>
奖励规则:

1. 登录专区可获5分/天(只限当天第一次登录)

2. 参与调研活动可获50积分/期(积分在调研结束后5个工作日内发放)

3. 参与当期问答,答对即可获得20积分/题
(每期答题满分100积分 共6期)

4. 有邀请码用户登录,奖励100积分(不累加)